Display options
Cite
Visser GH, de Valk HW. Gestational diabetes: screening for all, which test and which treatment?. Expert Rev Endocrinol Metab. 2012;7(2):165-167doi: 10.1586/eem.12.7.
Visser, G. H., & de Valk, H. W. (2012). Gestational diabetes: screening for all, which test and which treatment?. Expert review of endocrinology & metabolism, 7(2), 165-167. https://doi.org/10.1586/eem.12.7
Visser, Gerard Ha, and de Valk, Harold W. "Gestational diabetes: screening for all, which test and which treatment?." Expert review of endocrinology & metabolism vol. 7,2 (2012): 165-167. doi: https://doi.org/10.1586/eem.12.7
Visser GH, de Valk HW. Gestational diabetes: screening for all, which test and which treatment?. Expert Rev Endocrinol Metab. 2012 Mar;7(2):165-167. doi: 10.1586/eem.12.7. PMID: 30764007.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Endocrinol Metab. 2012 Mar;7(2):165-167. doi: 10.1586/eem.12.7.

Gestational diabetes: screening for all, which test and which treatment?.

Expert review of endocrinology & metabolism

Gerard Ha Visser, Harold W de Valk

Affiliations

  1. a Department of Obstetrics, University Medical Center, Utrecht, The Netherlands. [email protected].
  2. b Department of Internal Medicine, University Medical Center, Utrecht, The Netherlands.

PMID: 30764007 DOI: 10.1586/eem.12.7

Abstract

Gestational diabetes mellitus is rapidly increasing in incidence, due to lifestyle changes, increasing obesity and maternal age. This increase makes universal screening mandatory; however, we are still far from it. Moreover, should we adopt rather strict oral glucose tolerance test cutoff values, resulting in a worldwide incidence of gestational diabetes mellitus of approximately 17.5%, or should we be more liberal and focus more on patients and offspring at increased risk, for example, obese women. Finally, are oral antidiabetic drugs such as glyburide and metformin safe enough to use in gestational diabetes mellitus, or should they still be considered as the 'poor man's insulin'? These issues were presented and discussed during lively debates at the Controversies in Obstetrics, Gynecology and Infertility annual meetings, but consensus was not reached.

Keywords: gestational diabetes; oral antidiabetic drugs; screening

Publication Types